Wuhan YZY Biopharma Co Ltd (2496.HK) is a China-based biotechnology company focused on the discovery, development and commercialization of bispecific antibody (BsAb)-based therapies for cancer, cancer-related complications, age-related ophthalmologic diseases and autoimmune disorders; its core products include M701, a recombinant BsAb targeting EpCAM on cancer cells and CD3 on T cells primarily for malignant ascites (MA) and malignant pleural effusion (MPE), and Y101D, a recombinant anti-PD-L1/anti-TGF-β BsAb for pancreatic cancer and other solid tumors; additional pipelines encompass Y332 (anti-VEGF/anti-TGF-β BsAb for solid tumors), Y225 (Emicizumab biosimilar for hemophilia), Y232 (TL1A×X BsAb for inflammatory bowel disease) and others leveraging proprietary platforms such as Y-BODY, Check-Body and Nano-Ybody. Founded in 2010 and headquartered at No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Province, the company operates primarily in China with global rights retention for certain assets and overseas collaboration pursuits; it maintains in-house manufacturing facilities (500L scale) supplemented by CMO/CDMO partnerships and employs 106 staff as of mid-2025. Recent developments include granting exclusive domestic commercialization rights for M701 to CT Tianqing (a Sino Biopharmaceutical subsidiary) in October 2024 for upfront and milestone payments up to RMB1.015 billion plus royalties, completing Phase III enrollment for M701 in MA (312 subjects, BLA planned for 2025), advancing Phase II for M701 in MPE with ESMO 2025 interim data acceptance, finishing Phase Ib/II enrollment for Y101D in pancreatic cancer (CSR due by October 2025), completing Phase I for Y332, transferring Y400 rights to Shenzhen Kangzhe Vision and CMS R&D with ongoing Phase II in nAMD, securing patent grants for M701 formulations and sequences in China and Russia during 2025, and expecting IND approvals for Y225 by end-2025 and Y400 overseas milestones.